eligibility_summary
Advanced solid tumor with measurable disease (RECIST v1.1), ECOG 0–1, and adequate organ function. Excludes unresolved >Grade 1 toxicities, recent therapy (≤14 days small molecules/≤28 days biologics), progressive/symptomatic brain metastases, uncontrolled medical disease or infection, significant cardiac disease, MDS/AML, other cancers within 3 years (except low‑risk skin/DCIS/prostate ≤Gleason 6), and pregnancy or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial NCT05948826 tests TORL-3-600, a targeted biologic antibody–drug conjugate (ADC), as monotherapy in advanced solid tumors (including colorectal cancer). Mechanism of action: a monoclonal antibody binds a tumor-associated surface antigen (target not disclosed in registry), is internalized, and releases a cytotoxic payload inside the cancer cell, leading to cell death (e.g., via disruption of DNA replication or microtubules, payload not specified). Cells/pathways targeted: antigen-positive tumor cells, pathways include antigen-mediated binding, receptor-mediated endocytosis, lysosomal processing, and intracellular cytotoxic/apoptotic pathways. No immune checkpoint target noted. Phase 1 dose escalation/expansion.